Treosulfan
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Treosulfan: Diabetic cataract
One-Sentence Summary
Treosulfan is an alkylating agent marketed in India as an injectable. The TxGNN model predicts it may be effective for diabetic cataract, but this is a computational prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Diabetic cataract |
| TxGNN Prediction Score | 0.9901 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Treosulfan is a bifunctional alkylating agent: a prodrug that converts to epoxide intermediates which cross-link DNA. It is generally used in conditioning regimens before hematopoietic stem cell transplantation. This general description comes from background knowledge, not from the data compiled for this report.
A plausible mechanistic link to diabetic cataract cannot be established. Diabetic cataract is driven by polyol pathway activation, glycation and oxidative stress in the lens. DNA alkylation does not address these processes.
There is also a safety concern. Cataract is a known risk after conditioning regimens and with related alkylators such as busulfan, so lens toxicity could work against any benefit.
Other top-ranked predictions are:
None has trial or literature support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 74934 | Emtreo Injection (Emcure Pharmaceuticals Ltd) | Vial of 1 injection | Not stated in the license data |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent) |
| Myelosuppression Risk | High (profound myelosuppression is expected at conditioning doses; please confirm against the package insert) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | CBC with differential, liver and renal function |
| Handling Protection | Follow cytotoxic drug handling regulations |
Safety Considerations
Please refer to the package insert for safety information.
No drug interaction records were found. Lens toxicity is a theoretical concern for alkylating agents and should be assessed before any ophthalmic repurposing.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone, with no clinical trials, no literature and no supported mechanism. A systemic cytotoxic agent also has an unfavorable benefit-risk balance for cataract and diabetic eye disease, which are managed with surgery, anti-VEGF therapy and laser.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data, to test any biological link to lens or retinal disease
- Preclinical evidence of benefit, and a review of lens toxicity
- A feasibility assessment of a local ocular route, since only an injectable form is registered in India
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.